Microbot Medical® Added to the Russell Microcap® Index
Microbot Medical (Nasdaq: MBOT), developer of the LIBERTY® Endovascular Robotic System, has been added to the Russell Microcap® Index effective June 30, 2025. The inclusion comes at a strategic time as the company prepares for the anticipated Q3 launch of LIBERTY, which is currently pending FDA 510(k) clearance.
The Russell Microcap® Index is part of the annual Russell US Indexes reconstitution, which captures the 4,000 largest US stocks based on market capitalization. Russell indexes serve as benchmarks for approximately $10.6 trillion in assets as of June 2024, and are widely used by investment managers and institutional investors.
Microbot Medical (Nasdaq: MBOT), sviluppatore del sistema robotico endovascolare LIBERTY®, è stata inclusa nell'indice Russell Microcap® a partire dal 30 giugno 2025. Questa aggiunta avviene in un momento strategico, mentre l'azienda si prepara al previsto lancio nel terzo trimestre di LIBERTY, attualmente in attesa dell'approvazione FDA 510(k).
L'indice Russell Microcap® fa parte della ristrutturazione annuale degli indici Russell US, che comprende le 4.000 maggiori azioni statunitensi in base alla capitalizzazione di mercato. Gli indici Russell sono utilizzati come benchmark per circa 10,6 trilioni di dollari in asset a giugno 2024 e sono ampiamente adottati da gestori di investimenti e investitori istituzionali.
Microbot Medical (Nasdaq: MBOT), desarrollador del Sistema Robótico Endovascular LIBERTY®, ha sido incluido en el índice Russell Microcap® con efecto a partir del 30 de junio de 2025. Esta inclusión llega en un momento estratégico, ya que la compañía se prepara para el esperado lanzamiento en el tercer trimestre de LIBERTY, que actualmente está pendiente de la aprobación 510(k) de la FDA.
El índice Russell Microcap® forma parte de la reconstitución anual de los índices Russell de EE.UU., que abarca las 4,000 mayores acciones estadounidenses según su capitalización de mercado. Los índices Russell sirven como referencia para aproximadamente $10.6 billones en activos a junio de 2024, y son ampliamente utilizados por gestores de inversión e inversores institucionales.
Microbot Medical (Nasdaq: MBOT)는 LIBERTY® 혈관 내 로봇 시스템의 개발사로, 2025년 6월 30일부터 러셀 마이크로캡® 지수에 편입되었습니다. 이 편입은 회사가 현재 FDA 510(k) 승인을 기다리고 있는 LIBERTY의 3분기 출시를 준비하는 전략적인 시점에 이루어졌습니다.
러셀 마이크로캡® 지수는 매년 재구성되는 러셀 미국 지수의 일부로, 시가총액 기준 미국 내 상위 4,000개 주식을 포함합니다. 러셀 지수는 2024년 6월 기준 약 10.6조 달러 규모의 자산에 대한 벤치마크로 사용되며, 투자 관리자와 기관 투자자들 사이에서 널리 활용되고 있습니다.
Microbot Medical (Nasdaq : MBOT), développeur du système robotique endovasculaire LIBERTY®, a été ajouté à l'indice Russell Microcap® à compter du 30 juin 2025. Cette inclusion intervient à un moment stratégique, alors que la société se prépare au lancement prévu au troisième trimestre de LIBERTY, actuellement en attente de l'autorisation FDA 510(k).
L'indice Russell Microcap® fait partie de la reconstitution annuelle des indices Russell US, qui regroupe les 4 000 plus grandes actions américaines selon leur capitalisation boursière. Les indices Russell servent de référence pour environ 10,6 trillions de dollars d'actifs en juin 2024 et sont largement utilisés par les gestionnaires d'investissements et les investisseurs institutionnels.
Microbot Medical (Nasdaq: MBOT), Entwickler des LIBERTY® Endovaskulären Robotersystems, wurde zum 30. Juni 2025 in den Russell Microcap® Index aufgenommen. Die Aufnahme erfolgt zu einem strategisch günstigen Zeitpunkt, da das Unternehmen sich auf die erwartete Markteinführung von LIBERTY im dritten Quartal vorbereitet, die derzeit auf die FDA 510(k)-Zulassung wartet.
Der Russell Microcap® Index ist Teil der jährlichen Neuzusammensetzung der Russell US-Indizes, die die 4.000 größten US-Aktien nach Marktkapitalisierung abbilden. Russell-Indizes dienen als Benchmark für etwa 10,6 Billionen US-Dollar an Vermögenswerten per Juni 2024 und werden von Investmentmanagern und institutionellen Investoren weit verbreitet genutzt.
- None.
- LIBERTY is still pending FDA 510(k) clearance and not available for sale in the U.S.
Insights
Microbot's Russell Microcap inclusion increases visibility and potential institutional investment as they approach critical product launch.
Microbot Medical's addition to the Russell Microcap Index represents a significant milestone that extends beyond mere symbolism. This inclusion comes at a strategically important time as the company approaches its anticipated Q3 launch of the LIBERTY Endovascular Robotic System, pending FDA 510(k) clearance.
The Russell indexes are not simply academic listings - they drive approximately
Index inclusion also provides third-party validation of the company's market capitalization growth relative to peers, as Russell reconstitution uses objective methodology based on market cap rankings as of April 30th. Additionally, Microbot will benefit from automatic inclusion in corresponding growth and value style indexes, further expanding potential investor exposure.
The timing aligns perfectly with Microbot's developmental trajectory as they strengthen operational and commercial infrastructure ahead of their anticipated product launch. For a medical device company at this critical pre-commercialization stage, increased visibility to institutional investors could prove particularly valuable as they transition from development to commercialization phase.
Automatic inclusion in the appropriate growth and value style indexes
HINGHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced that it was added as a member of the Russell Microcap® Index. Microbot Medical’s addition will be effective today when the U.S. equity markets open.
“Inclusion in the Russell Microcap® Index marks another important milestone for Microbot Medical. It reflects the strong execution of our team and the momentum we have built, including our ongoing interaction with the FDA on our 510(k) submission for LIBERTY,” commented Harel Gadot, Chairman, CEO and President. “As we continue to prepare for our anticipated Q3 launch, we are focused on strengthening our operational and commercial infrastructure to ensure success. Being in the index, and the appropriate growth and value style indexes, enhances our visibility at a pivotal time, and we look forward to continued progress in the months ahead.”
The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Wednesday, April 30th, ranking them by total market capitalization. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell’s US indexes serve as the benchmark for about
LIBERTY is an investigational device pending FDA 510(k) clearance, and is currently not available for sale in the U.S.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to redefine endovascular robotics and improve the quality of care for millions of patients and providers globally. The Company has developed the world’s first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems.
Further information about Microbot Medical® is available at http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company’s need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY Endovascular Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will timely grant 510(k) clearance to commercially market the LIBERTY Endovascular Robotic System in the United States if at all, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Investor Contact:
FAQ
When was Microbot Medical (MBOT) added to the Russell Microcap Index?
What is the significance of MBOT joining the Russell Microcap Index?
What is the current status of Microbot Medical's LIBERTY® Endovascular Robotic System?
When is MBOT planning to launch the LIBERTY® Endovascular Robotic System?
What is the total asset value benchmarked to Russell indexes?
